Wells Fargo’s CorMedix CRMD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $542K | Buy |
68,996
+36,498
| +112% | +$288K | ﹤0.01% | 4563 |
|
|
2026
Q1 | $221K | Sell |
32,498
-54,002
| -62% | -$399K | ﹤0.01% | 4645 |
|
|
2025
Q4 | $1.01M | Buy |
86,500
+39,616
| +84% | +$438K | ﹤0.01% | 3968 |
|
|
2025
Q3 | $545K | Buy |
46,884
+12,200
| +35% | +$148K | ﹤0.01% | 4248 |
|
|
2025
Q2 | $427K | Buy |
34,684
+3,608
| +12% | +$39.8K | ﹤0.01% | 4255 |
|
|
2025
Q1 | $191K | Buy |
31,076
+655
| +2% | +$6.78K | ﹤0.01% | 4737 |
|
|
2024
Q4 | $246K | Buy |
30,421
+11,155
| +58% | +$111K | ﹤0.01% | 4667 |
|
|
2024
Q3 | $156K | Sell |
19,266
-216
| -1% | -$1.17K | ﹤0.01% | 4744 |
|
|
2024
Q2 | $84.4K | Buy |
19,482
+1,501
| +8% | +$7.63K | ﹤0.01% | 5041 |
|
|
2024
Q1 | $76.2K | Buy |
17,981
+2,223
| +14% | +$7.71K | ﹤0.01% | 5056 |
|
|
2023
Q4 | $59.3K | Buy |
15,758
+3,963
| +34% | +$13.6K | ﹤0.01% | 5205 |
|
|
2023
Q3 | $43.6K | Sell |
11,795
-7,875
| -40% | -$31.3K | ﹤0.01% | 5248 |
|
|
2023
Q2 | $78K | Buy |
19,670
+18,219
| +1,256% | +$90.1K | ﹤0.01% | 5187 |
|
|
2023
Q1 | $6.01K | Sell |
1,451
-5,996
| -81% | -$24.5K | ﹤0.01% | 6003 |
|
|
2022
Q4 | $31.4K | Buy |
7,447
+8
| +0.1% | +$28 | ﹤0.01% | 5075 |
|
|
2022
Q3 | $21K | Buy |
7,439
+6,014
| +422% | +$25K | ﹤0.01% | 5363 |
|
|
2022
Q2 | $5K | Sell |
1,425
-7,717
| -84% | -$28.7K | ﹤0.01% | 5994 |
|
|
2022
Q1 | $50K | Sell |
9,142
-13,549
| -60% | -$62K | ﹤0.01% | 5657 |
|
|
2021
Q4 | $104K | Buy |
22,691
+21,970
| +3,047% | +$109K | ﹤0.01% | 5609 |
|
|
2021
Q3 | $4K | Sell |
721
-146
| -17% | -$850 | ﹤0.01% | 6427 |
|
|
2021
Q2 | $5K | Sell |
867
-10,657
| -92% | -$84.8K | ﹤0.01% | 6330 |
|
|
2021
Q1 | $116K | Sell |
11,524
-24,394
| -68% | -$257K | ﹤0.01% | 5418 |
|
|
2020
Q4 | $266K | Buy |
35,918
+9,321
| +35% | +$63.4K | ﹤0.01% | 4926 |
|
|
2020
Q3 | $160K | Sell |
26,597
-5,524
| -17% | -$27.7K | ﹤0.01% | 5072 |
|
|
2020
Q2 | $202K | Sell |
32,121
-8,771
| -21% | -$40.6K | ﹤0.01% | 4904 |
|
|
2020
Q1 | $147K | Buy |
40,892
+20,353
| +99% | +$115K | ﹤0.01% | 4863 |
|
|
2019
Q4 | $150K | Sell |
20,539
-41,492
| -67% | -$254K | ﹤0.01% | 5115 |
|
|
2019
Q3 | $395K | Buy |
62,031
+37,685
| +155% | +$317K | ﹤0.01% | 4531 |
|
|
2019
Q2 | $218K | Buy |
24,346
+6,809
| +39% | +$53.4K | ﹤0.01% | 4930 |
|
|
2019
Q1 | $165K | Sell |
17,537
-3,631
| -17% | -$32.7K | ﹤0.01% | 4919 |
|
|
2018
Q4 | $136K | Buy |
21,168
+21,106
| +34,042% | +$141K | ﹤0.01% | 5132 |
|
|
2018
Q3 | $0 | Hold |
62
| – | – | ﹤0.01% | 6399 |
|
|
2018
Q2 | $0 | Hold |
62
| – | – | ﹤0.01% | 6349 |
|
|
2018
Q1 | $0 | Sell |
62
-3,000
| -98% | -$5.99K | ﹤0.01% | 6385 |
|
|
2017
Q4 | $8K | Hold |
3,062
| – | – | ﹤0.01% | 5962 |
|
|
2017
Q3 | $8K | Buy |
3,062
+2,400
| +363% | +$4.97K | ﹤0.01% | 5918 |
|
|
2017
Q2 | $1K | Hold |
662
| – | – | ﹤0.01% | 6105 |
|
|
2017
Q1 | $5K | Hold |
662
| – | – | ﹤0.01% | 6018 |
|
|
2016
Q4 | $5K | Hold |
662
| – | – | ﹤0.01% | 5948 |
|
|
2016
Q3 | $8K | Hold |
662
| – | – | ﹤0.01% | 5807 |
|
|
2016
Q2 | $7K | Sell |
662
-2,715
| -80% | -$41.3K | ﹤0.01% | 5743 |
|
|
2016
Q1 | $45K | Buy |
3,377
+2,680
| +385% | +$26K | ﹤0.01% | 5253 |
|
|
2015
Q4 | $7K | Sell |
697
-2,335
| -77% | -$26.9K | ﹤0.01% | 5806 |
|
|
2015
Q3 | $30K | Buy |
3,032
+2,121
| +233% | +$32.7K | ﹤0.01% | 5418 |
|
|
2015
Q2 | $18K | Buy |
911
+511
| +128% | +$17.5K | ﹤0.01% | 5629 |
|
|
2015
Q1 | $20K | Buy |
+400
| New | +$9.48K | ﹤0.01% | 5382 |
|
Other funds holding CRMD
DTC
RA
OAM
Wells Fargo's CRMD Position: Q2 2026 in Review
Wells Fargo increased its CorMedix (CRMD) stake by 112% in Q2 2026, buying an estimated $288K and bringing the position to 68,996 shares worth $542K. The position accounts for ﹤0.01% of the portfolio, ranked #4563.
Wells Fargo first reported a position in CRMD in Q1 2015 and has held it in 46 quarters since. The position peaked at $1.01M in Q4 2025. 194 funds tracked by Wall St. Rank hold CRMD as of Q2 2026.
- Wells Fargo held 68,996 shares of CorMedix worth $542K as of Q2 2026.
- Wells Fargo bought 36,498 CorMedix shares in Q2 2026, an estimated $288K.
- CorMedix made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #4563 holding.
- Wells Fargo first reported a position in CorMedix in Q1 2015 and has held it in 46 quarters since.
- Wells Fargo's CorMedix position peaked at $1.01M in Q4 2025.
- 194 funds tracked by Wall St. Rank held CorMedix as of Q2 2026.
Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.